Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

5.660 +0.280 (+5.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,524
Open 5.500
Bid (Size) 5.410 (1)
Ask (Size) 6.460 (1)
Prev. Close 5.380
Today's Range 5.320 - 5.660
52wk Range 4.750 - 10.69
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect. 
Via Benzinga

Performance

YTD
-0.88%
-0.88%
1 Month
+6.59%
+6.59%
3 Month
-41.23%
-41.23%
6 Month
-21.17%
-21.17%
1 Year
-5.51%
-5.51%

More News

Read More
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $10.0 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
From Coya Therapeutics, Inc.
Via Business Wire
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at Upcoming Healthcare Conferences
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
From Coya Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.